March 16, 2017 / 12:01 PM / in 4 months

BRIEF-Acceleron to initiate phase 2 trial of ACE-083 in charcot-marie-tooth neuromuscular disease

1 Min Read

March 16 (Reuters) - Acceleron Pharma Inc -

* Acceleron announces plans to initiate a phase 2 trial of ACE-083 in charcot-marie-tooth neuromuscular disease and host educational webinar

* Second phase 2 study for ACE-083 expected to begin 2H 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below